XTMAB-16: antibody-therapy research in a cell model
Translation of the existing Croatian article reporting research presented in 2022. Relative time expressions and quoted statements refer to that report.
Author: Dr Lindsey Shapiro – Antibody-based therapy prevents granuloma formation in a cell model
XTMAB-16, Xentria’s investigational antibody-based therapy for sarcoidosis, was able to reduce the formation of granulomas — abnormal clusters of immune cells that characterise the disease — in a patient-derived granuloma cell model, the company reported.
The data were presented in a poster entitled “XTMAB-16 Attenuates Formation Granuloma in a Human In Vitro Sarcoidosis Model” at the American Thoracic Society’s 2022 International Conference in San Francisco on 17 May.
“These new data are a promising first step in the ongoing evaluation of XTMAB-16 as a potential therapy for patients with sarcoidosis,” Thomas Shea, president of Xentria, said in a press release. “The publication of these new data reinforces our commitment to the rare-disease sarcoidosis community and our mission to develop new breakthrough treatments.”
The accumulation of granulomas damages the normal function of various tissues and can affect the function of almost any organ in the body, most commonly the lungs.
By suppressing the activity of TNF-alpha, a pro-inflammatory molecule that contributes to swelling, inflammation and granuloma formation, XTMAB-16 is expected to relieve symptoms.
Although no TNF-alpha inhibitors are currently approved in the United States for treating sarcoidosis, a previous study showed that around 10% of patients are treated with such therapies off label. In 2020, the US Food and Drug Administration granted XTMAB-16 orphan-drug designation for the treatment of sarcoidosis, intended to accelerate the therapy’s development.
Researchers from Xentria and Ohio State University evaluated the effects of XTMAB-16 on granuloma formation in a cell-culture granuloma model. To create it, cells were obtained from 10 patients with sarcoidosis involving the lungs and/or lymph nodes and incubated with a protein to induce granuloma formation and the release of inflammatory molecules.
When the cells were pretreated with XTMAB-16 at doses ranging from 1 microgram per millilitre (mcg/mL) to 40 mcg/mL, granuloma formation was significantly reduced in a dose-dependent manner compared with untreated cells. The release of inflammatory molecules was also inhibited when the cells were treated with XTMAB-16.
The effects of XTMAB at higher doses were comparable to those observed with the corticosteroid prednisone, Xentria said. Corticosteroids are frequently used to treat sarcoidosis but can result in serious and significant adverse effects.
“Although medicines are currently available that attempt to control the symptoms of this rare disease, the available treatments have serious limitations, including limited efficacy and unacceptable adverse effects, and there is an urgent need for better treatments,” said Elliott D. Crouser, MD, professor of internal medicine at Ohio State University’s Wexner Medical Center. Crouser is also one of the study’s investigators.
The efficacy of XTMAB-16 in reducing disease activity in humans will need to be established in clinical trials, Xentria said.
Last year, Xentria announced a planned Phase 1 trial (NCT04971395) to evaluate the safety and tolerability of multiple doses of XTMAB-16 in healthy volunteers. Secondary objectives included pharmacokinetics — the movement of a therapy into, through and out of the body — immune reactions against the therapy, and disease-biomarker levels.
The trial enrolled 25 adults aged 18 to 45, who were randomly assigned to receive a single injection of XTMAB-16 into a vein (2 or 4 mg/kg) or a placebo. It was completed in March, and results are expected next year, according to Xentria.
Source: https://sarcoidosisnews.com/news/sarcoidosis-therapy-xtmab-16-stops-granuloma-formation-cell-model/